PMID- 35402591
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 5
DP  - 2022 Mar
TI  - 5-methylcytosine RNA methylation regulators affect prognosis and tumor 
      microenvironment in lung adenocarcinoma.
PG  - 259
LID - 10.21037/atm-22-500 [doi]
LID - 259
AB  - BACKGROUND: Accumulating evidence has shown that 5-methylcytosinec (m5C) RNA 
      methylation plays an essential role in tumorigenesis. However, the roles of m5C 
      regulators in the prognosis, tumor microenvironment (TME), and immunotherapy 
      responses of lung adenocarcinoma (LUAD) have not been fully analyzed. METHODS: 
      Based on 14 m5C RNA regulators, we evaluated the m5C RNA modification patterns in 
      patients with LUAD (n=594) in The Cancer Genome Atlas (TCGA). Unsupervised 
      clustering analysis was performed to confirm distinct m5C modification patterns. 
      Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment 
      analyses were performed to investigate the biological functions of differentially 
      expressed genes (DEGs) among different m5C RNA modification patterns. An m5C 
      signature (m5Csig) was constructed using least absolute shrinkage and selection 
      operator (LASSO) algorithms. The GSE72094 cohort (n=442) from the Gene Expression 
      Omnibus (GEO) was used to validate m5Csig. A receiver operating characteristic 
      (ROC) model was constructed to evaluate the sensitivity and specificity of 
      m5Csig. Tumor-infiltrating immune cells (TIICs) between the high- and low-risk 
      groups were estimated using the Cell Type Identification By Estimating Relative 
      Subsets Of RNA Transcripts (CIBERSORT) algorithm. RESULTS: We identified 3 m5C 
      RNA modification clusters. Overall survival (OS) differed among the 3 clusters. 
      The m5Csig, including TRDMT1, NSUN1, NSUN4, NSUN7, and ALYREF, was constructed to 
      classify patients with LUAD into high- and low-risk groups. The high-risk group, 
      with more immune cell infiltration, had a significantly poorer OS than that the 
      low-risk group, which was associated with better response to immune checkpoint 
      blockade therapy. CONCLUSIONS: The present study revealed that m5C RNA regulators 
      play a significant role in TME regulation in LUAD. The m5Csig can predict the 
      prognosis of patients with LUAD and might provide novel strategies for tumor 
      immunotherapy.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Liu, Taisheng
AU  - Liu T
AD  - Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
AD  - Department of Thoracic Surgery, Affiliated Cancer Hospital & Institute of 
      Guangzhou Medical University, Guangzhou, China.
FAU - Hu, Xiaoshan
AU  - Hu X
AD  - Department of Internal Medicine of Oncology, Affiliated Cancer Hospital & 
      Institute of Guangzhou Medical University, Guangzhou, China.
FAU - Lin, Chunxuan
AU  - Lin C
AD  - Department of Pneumology, Guangdong Provincial Hospital of Integrated Traditional 
      Chinese and Western Medicine, Foshan, China.
FAU - Shi, Xiaoshun
AU  - Shi X
AD  - Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - He, Yujing
AU  - He Y
AD  - Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of 
      Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, 
      Guangzhou Institute of Respiratory Disease, Guangzhou, China.
AD  - Guangzhou Medical University, Guangzhou, China.
FAU - Cai, Kaican
AU  - Cai K
AD  - Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC8987885
OTO - NOTNLM
OT  - 5-methylcytosine RNA methylation
OT  - Lung adenocarcinoma (LUAD)
OT  - immunotherapy
OT  - tumor microenvironment
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-500/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/03/01
CRDT- 2022/04/11 05:32
PHST- 2022/01/10 00:00 [received]
PHST- 2022/03/04 00:00 [accepted]
PHST- 2022/04/11 05:32 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - atm-10-05-259 [pii]
AID - 10.21037/atm-22-500 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Mar;10(5):259. doi: 10.21037/atm-22-500.